The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Thorsten Simon

Children's Hospital

University of Cologne

Cologne

Germany

[email]@uk-koeln.de

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Children's Hospital, University of Cologne, Cologne, Germany. 2005 - 2011
  • Department of Pediatric Oncology and Hematology, Children's Hospital, University of Cologne, Cologne, Germany. 2004 - 2011

References

  1. Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy. Simon, T., Hero, B., Faldum, A., Handgretinger, R., Schrappe, M., Klingebiel, T., Berthold, F. BMC. Cancer (2011) [Pubmed]
  2. Treatment and outcomes of patients with relapsed, high-risk neuroblastoma: results of German trials. Simon, T., Berthold, F., Borkhardt, A., Kremens, B., De Carolis, B., Hero, B. Pediatr. Blood. Cancer (2011) [Pubmed]
  3. Multiple malignant diseases in a patient with Rothmund-Thomson syndrome with RECQL4 mutations: Case report and literature review. Simon, T., Kohlhase, J., Wilhelm, C., Kochanek, M., De Carolis, B., Berthold, F. Am. J. Med. Genet. A (2010) [Pubmed]
  4. Review of image defined risk factors in localized neuroblastoma patients: Results of the GPOH NB97 trial. Simon, T., Hero, B., Benz-Bohm, G., von Schweinitz, D., Berthold, F. Pediatr. Blood. Cancer (2008) [Pubmed]
  5. Topotecan, cyclophosphamide, and etoposide (TCE) in the treatment of high-risk neuroblastoma. Results of a phase-II trial. Simon, T., Längler, A., Harnischmacher, U., Frühwald, M.C., Jorch, N., Claviez, A., Berthold, F., Hero, B. J. Cancer Res. Clin. Oncol. (2007) [Pubmed]
  6. Topotecan and etoposide in the treatment of relapsed high-risk neuroblastoma: results of a phase 2 trial. Simon, T., Längler, A., Berthold, F., Klingebiel, T., Hero, B. J. Pediatr. Hematol. Oncol. (2007) [Pubmed]
  7. Risk estimation in localized unresectable single copy MYCN neuroblastoma by the status of chromosomes 1p and 11q. Simon, T., Spitz, R., Hero, B., Berthold, F., Faldum, A. Cancer Lett. (2006) [Pubmed]
  8. Intensified external-beam radiation therapy improves the outcome of stage 4 neuroblastoma in children > 1 year with residual local disease. Simon, T., Hero, B., Bongartz, R., Schmidt, M., Müller, R.P., Berthold, F. Strahlenther. Onkol (2006) [Pubmed]
  9. Infants with stage 4 neuroblastoma: the impact of the chimeric anti-GD2-antibody ch14.18 consolidation therapy. Simon, T., Hero, B., Faldum, A., Handgretinger, R., Schrappe, M., Niethammer, D., Berthold, F. Klin. Padiatr (2005) [Pubmed]
  10. Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma. Simon, T., Hero, B., Faldum, A., Handgretinger, R., Schrappe, M., Niethammer, D., Berthold, F. J. Clin. Oncol. (2004) [Pubmed]
  11. New definition of low-risk neuroblastoma using stage, age, and 1p and MYCN status. Simon, T., Spitz, R., Faldum, A., Hero, B., Berthold, F. J. Pediatr. Hematol. Oncol. (2004) [Pubmed]
 
WikiGenes - Universities